Exploratory investigation of discovering novel biomarker to predict efficacy of chemotherapy including bevacizumab in patients with advanced ovarian cancer

Hirakawa Takashi0 个研究点目标入组 2 人开始时间: 2019年3月25日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 2

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

This clinical trial was aimed to searching for biomarkers in patients treated with bevacizumab for advanced ovarian cancer. The enrollment was discontinued due to avoidance of bevacizumab-specific adverse events and a change in treatment strategy due to the introduction of new drugs.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20age 至 ot applicable（—）
性别: Female

入选标准

•1) Pathologically confirmed advanced ovarian cancer with stage III/IV
•2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
•3) Patient with evaluable lesion based on RECIST
•4) Written informed consent

排除标准

•1) Pregnant woman
•2) Patients with double primary cancer or serious infectious disease requiring antibiotic therapy
•3) Other cases attending physician it is determined unsuitable for registration of the study

研究者

发起方

Hirakawa Takashi

相似试验

已完成

不适用

Clinical effects and biomarkers of biological agents on asthmaBronchial asthmaasthma

JPRN-jRCT1031190033MORI AKIO12

招募中

不适用

Discovery of proteins that differentiate health and disease around dental implantsPeri-ImplantitisE06.780.346.593

RBR-99xvpphniversidade Estadual de Maringá

Unknown

不适用

Study for the Validation of a New Biomarker to Determine Predisposition to Infections in Patients With Acute Myocardial Infarction.Infections in Acute Myocardial Infarction Patients

NCT05412732Instituto de Investigación Hospital Universitario La Paz300

已完成

不适用

Research for new biomarker about diagnosis and evaluation of disease condition for inflammatory bowel disease (IBD).Inflammatory bowel disease

JPRN-UMIN000017831Kyoto Prefectural University of Medicine400

尚未招募

Unknown

Exploratory research of biomarkers for investigational drugs using tear fluid samplesMeibomian Gland Dysfunction

JPRN-UMIN000049186Santen Pharmaceutical Co. Ltd.29